Dept. of Justice to probe Plavix settlement

Share this article:
FBI agents raided the office of Bristol-Myers Squibb CEO Peter Dolan late last week as part of a criminal probe into the deal the company struck to stave off generic competition for its top-selling Rx drug product, the blood thinner Plavix. The probe concerns a settlement reached in March between Bristol, Plavix marketing partner Sanofi-Aventis and the generic drugmaker Apotex. Under the deal, Apotex, which received FDA approval to market a generic version of Plavix in March, said it would not begin selling its copycat version of the drug until 2011. The deal last week failed to receive required antitrust clearance from the US state attorneys general. Plavix accounts for 30% of Bristol's profits with global sales of over $5 billion, making it one of the world’s top three best-selling prescription drugs.
Share this article:
You must be a registered member of MMM to post a comment.

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.